Tom Vanden Boom to join the Hospira as Global Pharmaceuticals Vice President of Biologics R&D

Life Science Partner recruits former Director of the Biologics Manufacturing Launch Teams at Bristol-Myers Squibb Company

Life Science Partner announces the recruitment of Tom Vanden Boom, PhD, a senior biopharmaceutical executive in the development, manufacturing and commercial launch of biologic products.  Hospira is a global specialty pharmaceutical and medication delivery company that develops, manufactures and markets products that help improve the safety, effectiveness and costs of patient care.

In his most recent role at Bristol-Myers Squibb, Vanden Boom was responsible for leading the Biologics Manufacturing Launch Teams for global technical operations manufacturing and supply chain activities supporting the commercial launch of all new biologic products for the company.   Prior to his tenure at Bristol-Myers Squibb, Vanden Boom served as the Department Head of Biological Development at Abbott Laboratories.  In his new role at Hospira, he will provide strategic and technical leadership for the company’s drive to develop biosimilars drugs for some of the world’s blockbuster biological drugs.

“Vanden Boom is a talented strategic leader with an established track record of building highly successful teams and managing complex biological projects,” noted Tom Callaway, President of Life Science Partner.  “His considerable technical and business expertise in the development of biopharmaceuticals will serve Hospira well in its mission to become a global leader in providing biosimilar versions of the world’s most critical biological drugs.”

Vanden Boom earned a Bachelor of Science degree in Biochemistry and a Masters in Bacteriology from the University of Wisconsin – Madison.  He received his PhD in Microbiology from the University of Illinois at Urbana-Champaign.  There, he also completed a post-doctoral in Molecular Genetics.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply